Latest Conference Articles

Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.

Dr. Lisa A. Carey Discusses Psycho-Oncology

March 8th 2013, 12:26pm

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Coping With Burnout? Tips on Handling This Occupational Hazard

March 8th 2013, 8:54am

Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.

Side Effects With Regorafenib Occur Early and Tend to Taper

March 8th 2013, 8:17am

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Dr. Rugo on the Standard for Front-Line Chemotherapy

March 8th 2013, 7:16am

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

Surprises and Advances Mark Top Abstracts of 2012

March 7th 2013, 2:49pm

An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.

Similar Benefit, Lower Toxicity Found With Capecitabine- Versus Gemcitabine-based Chemoradiation in Pancreatic Cancer

March 6th 2013, 3:33pm

Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.

Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC

March 5th 2013, 7:49am

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Complete Neoadjuvant Chemotherapy May Offer New Framework for Treating Rectal Cancer

March 4th 2013, 1:13pm

Complete neoadjuvant treatment may represent a well-tolerated alternative to the current standard treatment sequence of adjuvant chemotherapy following chemoradiation and surgery.

Dr. Huang Compares Surveillance and Treatment in Kidney Cancer

February 18th 2013, 11:22am

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

The 2013 Genitourinary Cancers Symposium

February 18th 2013, 9:31am

The 2013 Genitourinary Cancers Symposium was held at the Rosen Shingle Creek, Orlando, Florida, from February 14-16.

Dr. Cooperberg on Earlier Treatment With Sipuleucel-T

February 16th 2013, 5:55pm

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

PFS Not Significantly Better With First-Line Axitinib Versus Sorafenib in mRCC

February 16th 2013, 12:58pm

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

No Survival Advantage for Tivozanib Over Sorafenib in TIVO-1 Study

February 16th 2013, 11:49am

Tivozanib did not show a significant difference in overall survival when compared with sorafenib in patients with renal cell carcinoma who received up to one prior line of therapy excluding targeted agents.

Dr. Vogelzang Discusses Radium-223 in Prostate Cancer

February 16th 2013, 11:16am

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Tandems of Targeted Therapy No Better Than Bevacizumab Alone in Advanced Renal Cell Carcinoma

February 16th 2013, 8:35am

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Dr. Scher on Corticosteroids and Enzalutamide in mCRPC

February 15th 2013, 1:20pm

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

Dr. Motzer Analyzes Overall Survival in the TIVO-1 Study

February 15th 2013, 1:20pm

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

Dasatinib Combination Fails to Improve Outcomes in mCRPC

February 15th 2013, 1:20pm

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

Abiraterone Continues to Show Survival Benefit in Updated Interim Analysis

February 15th 2013, 9:24am